vs

Side-by-side financial comparison of iQSTEL Inc (IQST) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.

Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $84.2M, roughly 1.9× iQSTEL Inc). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -3.2%, a 74.4% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs -14.9%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-1.2M).

iQSTEL Inc is a technology holding company operating three core segments: telecommunications, Internet of Things (IoT), and fintech. It offers connectivity services, smart IoT monitoring solutions, and digital financial tools, mainly serving small and medium-sized enterprises and retail customers in North and South American markets.

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.

IQST vs STOK — Head-to-Head

Bigger by revenue
STOK
STOK
1.9× larger
STOK
$158.6M
$84.2M
IQST
Growing faster (revenue YoY)
STOK
STOK
+3676.0% gap
STOK
3661.1%
-14.9%
IQST
Higher net margin
STOK
STOK
74.4% more per $
STOK
71.2%
-3.2%
IQST
More free cash flow
STOK
STOK
$132.9M more FCF
STOK
$131.7M
$-1.2M
IQST

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
IQST
IQST
STOK
STOK
Revenue
$84.2M
$158.6M
Net Profit
$-2.7M
$112.9M
Gross Margin
3.5%
Operating Margin
-2.9%
70.2%
Net Margin
-3.2%
71.2%
Revenue YoY
-14.9%
3661.1%
Net Profit YoY
-44.5%
528.0%
EPS (diluted)
$-0.92
$1.90

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IQST
IQST
STOK
STOK
Q4 25
$84.2M
Q3 25
$102.9M
Q2 25
$72.2M
Q1 25
$57.6M
$158.6M
Q4 24
$98.9M
$22.6M
Q3 24
$54.2M
Q2 24
$78.6M
Q1 24
$51.4M
Net Profit
IQST
IQST
STOK
STOK
Q4 25
$-2.7M
Q3 25
$-2.3M
Q2 25
$-2.3M
Q1 25
$-1.1M
$112.9M
Q4 24
$-1.9M
$-10.5M
Q3 24
$-773.0K
Q2 24
$-2.0M
Q1 24
$-580.2K
Gross Margin
IQST
IQST
STOK
STOK
Q4 25
3.5%
Q3 25
2.7%
Q2 25
2.6%
Q1 25
3.4%
Q4 24
2.7%
Q3 24
3.7%
Q2 24
2.8%
Q1 24
2.7%
Operating Margin
IQST
IQST
STOK
STOK
Q4 25
-2.9%
Q3 25
-0.5%
Q2 25
-0.9%
Q1 25
-1.0%
70.2%
Q4 24
-0.3%
-60.4%
Q3 24
-0.1%
Q2 24
-0.4%
Q1 24
-0.4%
Net Margin
IQST
IQST
STOK
STOK
Q4 25
-3.2%
Q3 25
-2.3%
Q2 25
-3.3%
Q1 25
-2.0%
71.2%
Q4 24
-1.9%
-46.4%
Q3 24
-1.4%
Q2 24
-2.5%
Q1 24
-1.1%
EPS (diluted)
IQST
IQST
STOK
STOK
Q4 25
$-0.92
Q3 25
$-0.68
Q2 25
$-0.82
Q1 25
$-0.44
$1.90
Q4 24
$-1.19
$-0.15
Q3 24
$-0.40
Q2 24
$-0.90
Q1 24
$-0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IQST
IQST
STOK
STOK
Cash + ST InvestmentsLiquidity on hand
$2.2M
$274.8M
Total DebtLower is stronger
$4.1M
Stockholders' EquityBook value
$16.3M
$350.1M
Total Assets
$51.1M
$406.9M
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IQST
IQST
STOK
STOK
Q4 25
$2.2M
Q3 25
$2.3M
Q2 25
$2.0M
Q1 25
$1.1M
$274.8M
Q4 24
$2.5M
$128.0M
Q3 24
$2.1M
Q2 24
$797.2K
Q1 24
$2.7M
Total Debt
IQST
IQST
STOK
STOK
Q4 25
$4.1M
Q3 25
$2.7M
Q2 25
$4.5M
Q1 25
$3.5M
Q4 24
$2.5M
Q3 24
$3.2M
Q2 24
$2.5M
Q1 24
$194.0K
Stockholders' Equity
IQST
IQST
STOK
STOK
Q4 25
$16.3M
Q3 25
$17.9M
Q2 25
$14.3M
Q1 25
$11.6M
$350.1M
Q4 24
$11.9M
$229.0M
Q3 24
$8.1M
Q2 24
$7.6M
Q1 24
$8.4M
Total Assets
IQST
IQST
STOK
STOK
Q4 25
$51.1M
Q3 25
$46.9M
Q2 25
$51.4M
Q1 25
$42.0M
$406.9M
Q4 24
$79.0M
$271.6M
Q3 24
$32.4M
Q2 24
$30.0M
Q1 24
$22.1M
Debt / Equity
IQST
IQST
STOK
STOK
Q4 25
0.25×
Q3 25
0.15×
Q2 25
0.31×
Q1 25
0.31×
Q4 24
0.21×
Q3 24
0.40×
Q2 24
0.34×
Q1 24
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IQST
IQST
STOK
STOK
Operating Cash FlowLast quarter
$-1.2M
$131.8M
Free Cash FlowOCF − Capex
$-1.2M
$131.7M
FCF MarginFCF / Revenue
-1.5%
83.0%
Capex IntensityCapex / Revenue
0.0%
0.1%
Cash ConversionOCF / Net Profit
1.17×
TTM Free Cash FlowTrailing 4 quarters
$-4.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IQST
IQST
STOK
STOK
Q4 25
$-1.2M
Q3 25
$-953.0K
Q2 25
$257.7K
Q1 25
$-1.9M
$131.8M
Q4 24
$-403.7K
$-23.2M
Q3 24
$625.0K
Q2 24
$-2.6M
Q1 24
$-536.9K
Free Cash Flow
IQST
IQST
STOK
STOK
Q4 25
$-1.2M
Q3 25
$-969.2K
Q2 25
$211.7K
Q1 25
$-2.0M
$131.7M
Q4 24
$-421.3K
$-23.2M
Q3 24
$594.5K
Q2 24
$-2.6M
Q1 24
$-608.5K
FCF Margin
IQST
IQST
STOK
STOK
Q4 25
-1.5%
Q3 25
-0.9%
Q2 25
0.3%
Q1 25
-3.4%
83.0%
Q4 24
-0.4%
-102.7%
Q3 24
1.1%
Q2 24
-3.4%
Q1 24
-1.2%
Capex Intensity
IQST
IQST
STOK
STOK
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.1%
Q1 25
0.1%
0.1%
Q4 24
0.0%
0.2%
Q3 24
0.1%
Q2 24
0.0%
Q1 24
0.1%
Cash Conversion
IQST
IQST
STOK
STOK
Q4 25
Q3 25
Q2 25
Q1 25
1.17×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IQST
IQST

USA$53.2M63%
Other$29.9M35%
Switzerland$1.1M1%

STOK
STOK

Segment breakdown not available.

Related Comparisons